Cancer Care Ontario | Cancer Care Ontario

278 Results

Regimen

BEACOPDAC-14

Cancer Type:

Hematologic,

Lymphoma - Hodgkin

Show More Show more tags

, Show Less Show fewer tags

Intent: Curative

Funding:

ODB - General Benefit

prednisone

Show More Show more tags

, Show Less Show fewer tags

Drugs Used:

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Aug 2023

Regimen

LENV+PEMB

Cancer Type:

Genitourinary,

Renal cell / Kidney

Show More Show more tags

, Show Less Show fewer tags

Intent: Palliative

Funding:

Exceptional Access Program

lenvatinib - In Combination with Pembrolizumab for First-Line Advanced or Metastatic Renal Cell Carcinoma

New Drug Funding Program

Pembrolizumab - In Combination with Lenvatinib for First-Line Advanced or Metastatic Renal Cell Carcinoma

Show More Show more tags

, Show Less Show fewer tags

Drugs Used:

lenvatinib,

pembrolizumab

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Aug 2023

Guidelines and Advice

An Endorsement of the 2022 NCCN Guideline on Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)

Status: Current
ID: GL-END-C50-35

Aug 2023

Guidelines and Advice

Ontario Health (Cancer Care Ontario) Endorsement of ASCO Rapid Recommendation on 177Lutetium-Prostate-Specific Membrane Antigen-617 (PSMA-617) for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Status: Current
ID: GL-END 3-25

Nov 2023

Guidelines and Advice

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines January to June 2023

Status: Current
ID: PET 2023-1

Nov 2023

Regimen

BORTDEXALENA(LD)

Cancer Type:

Hematologic,

Multiple Myeloma

Show More Show more tags

, Show Less Show fewer tags

Intent: Palliative

Funding:

New Drug Funding Program

Bortezomib - In Combination with Lenalidomide and Dexamethasone for Previously Untreated Multiple Myeloma Pre-SCT

ODB Limited Use

lenalidomide - Induction therapy for transplant eligible, newly diagnosed multiple myeloma, according to clinical criteria

ODB - General Benefit

dexamethasone

Show More Show more tags

, Show Less Show fewer tags

Drugs Used:

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Dec 2023

Guidelines and Advice

T-Cell Engaging Antibodies: Management of Cytokine Release Syndrome (CRS) and Immune Effector-Associated Neurotoxicity Syndrome (ICANS)

Status: Current

Mar 2025

Guidelines and Advice

Ontario Cervical Screening Program: Interim guidance to support the transition years following the launch of human papillomavirus testing in Ontario: Cervical screening and colposcopy recommendations for people ages 21 to 24

Status: Current

Mar 2025

Regimen

VORA

Cancer Type:

Central Nervous System

Show More Show more tags

, Show Less Show fewer tags

Intent: Curative, Palliative

Drugs Used:

vorasidenib (Unfunded)

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Mar 2025

Guidelines and Advice

An Endorsement of the 2023 International Stereotactic Radiosurgery Society’s (ISRS) Guideline: A Systematic Review Informing the Management of Symptomatic Brain Radiation Necrosis After Stereotactic Radiosurgery and ISRS Recommendations

Status: Current
ID: Guideline Endorsement C50-CIDAP-3

Mar 2025

Guidelines and Advice

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines January to June 2024

Status: Current
ID: PET 2024-1

Mar 2025

Guidelines and Advice

Preoperative Breast Magnetic Resonance Imaging

Status: Current
ID: GL 1-25
Version: N/A

Mar 2023

BEACOPDAC-14

LENV+PEMB

An Endorsement of the 2022 NCCN Guideline on Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)

Ontario Health (Cancer Care Ontario) Endorsement of ASCO Rapid Recommendation on 177Lutetium-Prostate-Specific Membrane Antigen-617 (PSMA-617) for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines January to June 2023

BORTDEXALENA(LD)

T-Cell Engaging Antibodies: Management of Cytokine Release Syndrome (CRS) and Immune Effector-Associated Neurotoxicity Syndrome (ICANS)

Ontario Cervical Screening Program: Interim guidance to support the transition years following the launch of human papillomavirus testing in Ontario: Cervical screening and colposcopy recommendations for people ages 21 to 24

VORA

An Endorsement of the 2023 International Stereotactic Radiosurgery Society’s (ISRS) Guideline: A Systematic Review Informing the Management of Symptomatic Brain Radiation Necrosis After Stereotactic Radiosurgery and ISRS Recommendations

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines January to June 2024

Preoperative Breast Magnetic Resonance Imaging

Pages